Anti-LYVE1

Anti-LYVE1
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
NSJ-R36081-100UG 100 µg - -

3 - 10 Werktage*

755,00 €
 
0.5 mg/ml in 1X TBS, pH7.3, with 0.5% BSA (US sourced) and 0.02% sodium azide. Additional name(s)... mehr
Produktinformationen "Anti-LYVE1"
0.5 mg/ml in 1X TBS, pH7.3, with 0.5% BSA (US sourced) and 0.02% sodium azide. Additional name(s) for this target protein: Lymphatic vessel endothelial hyaluronan receptor 1 Protein function: Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes. [The UniProt Consortium]
Schlagworte: Anti-LYVE1, Anti-CRSBP1, Anti-LYVE-1, Anti-CRSBP-1, Anti-Hyaluronic acid receptor, Anti-Extracellular link domain-containing protein 1, Anti-Cell surface retention sequence-binding protein 1, Anti-Lymphatic vessel endothelial hyaluronic acid receptor 1, L
Hersteller: NSJ Bioreagents
Hersteller-Nr: R36081

Eigenschaften

Anwendung: WB, ELISA (peptide)
Antikörper-Typ: Polyclonal
Konjugat: No
Wirt: Goat
Spezies-Reaktivität: human
Immunogen: Amino acids STETEPFVENK were used as the immunogen for this LYVE1 antibody. The amino acid sequence used as immunogen is from the extracellular portion of the protein.
Format: Purified

Handhabung & Sicherheit

Lagerung: -20°C
Versand: +4°C (International: +4°C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Anti-LYVE1"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen